Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC

Tislelizumab in oesophageal cancer after systemic therapy

OncoAlert and ecancer ASCO roundup - Day 3

PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

Incidence and trends of HPV-related cancers in the United States

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers